Loading organizations...
Loading organizations...
Empowering women. Period.
Key people at Qvin.
Qvin was founded in 2014 by Sara Naseri (Founder) and Søren Therkelsen (Founder).
Qvin is the first and only healthcare service to scientifically prove menstrual blood can test for critical health information – just like a traditional laboratory blood test.
Women's health has always been under-prioritized in science. We still operate in a world built by men, for men. It’s why in 2014, Dr. Sara Naseri and Søren Therkelsen started Qvin to research, develop, and patent a product that powers an underserved and understudied population:women.
Over 70% of the decisions our doctors make are influenced by blood test results. Every month, 1.8 billion people across the world menstruate. However, the blood our bodies naturally deliver every month has never been explored as a testing source. And yet, menstrual blood has been left unexplored.
Qvin is the first and only healthcare service to use period blood as a non-invasive blood test. We exist to give women an easy, insightful way to monitor existing health issues, proactively screen for others, and go into doctor visits more informed and confident of their own health.
Our health technology platform helps women manage their health better through a non-invasive blood collection device named the Q-Pad™.
All of us at Qvin want to move the study of women forward. We want to close the gender data gap. And we stand for every person who identifies with women, however they define it.
Key people at Qvin.
Qvin is a pioneering health technology company that empowers women by transforming menstrual blood into a non-invasive diagnostic tool. Their flagship product, the Q-Pad™, is the first and only FDA-cleared menstrual pad scientifically proven to collect menstrual blood for laboratory testing, enabling users to monitor critical health biomarkers such as A1c for diabetes, anemia, fertility, and thyroid health. Serving people who menstruate globally, Qvin addresses the longstanding gender data gap in healthcare by providing an accessible, needle-free way to gain health insights, thus improving early detection and ongoing health management[1][2][5].
Founded in 2014 by Dr. Sara Naseri, a medical doctor and scientist, and Søren Therkelsen, Qvin emerged from the recognition that menstrual blood, despite being produced monthly by 1.8 billion people worldwide, had never been utilized as a diagnostic resource. Their patented technology and research have led to FDA clearance and significant early traction, including media recognition and adoption in clinical research settings. This breakthrough has positioned Qvin as a leader in women's health innovation, with a growing team and expanding biomarker testing capabilities[1][3][4].
Qvin rides the growing trend of personalized, non-invasive health monitoring and the increasing focus on women's health equity. The timing is critical as awareness of the gender data gap in medicine rises alongside advances in biotechnology and digital health platforms. Market forces favor innovations that reduce healthcare costs and improve accessibility, especially for underserved populations. By leveraging menstrual blood—a previously untapped biological resource—Qvin is reshaping diagnostics and empowering individuals with actionable health data, influencing both clinical research and consumer health ecosystems[1][8][9].
Looking ahead, Qvin is poised to expand its diagnostic capabilities and global reach, potentially transforming routine health monitoring for billions of menstruators worldwide. Trends such as telemedicine, digital health integration, and increased investment in women’s health innovation will shape their journey. As Qvin continues to close the gender data gap and democratize health insights, their influence is likely to grow beyond diagnostics into broader health management and research domains, reinforcing their mission to empower women—period[3][5][10].
Qvin was founded in 2014 by Sara Naseri (Founder) and Søren Therkelsen (Founder).
